The Feasibility Study of Adjuvant nab-paclitaxel+Carboplatin in Patients with Resected Stage IB-IIIA Non-Small-Cell Lung Cance

Phase 2

• Conditions: non-small cell lung cancer

• Registration Number: JPRN-UMIN000011315
• Lead Sponsor: Hiroshima University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-09-05
• Study Completion: 2017-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

1) Allergy for CBDCA/nab-paclitaxel 2) History of Severe drug allergies 3) Myocardial infarction within 6 months 4) Interstitial pneumonia or pulmonary fibrosis detectable on X ray 5)Severe concurrent disease (Ischemic heart disease requiring treatment,arrhythmia,cardiac infarction within 6months before enrollment,hepatic failure,hemorrhagic peptic ulcer,poorly controlled diabetes) 6) History of active double cancerwithin 5years prior to the study 7) HBV-positive patients 8) Patients who are pregnant,considering pregnancy oractaing 9) Other conditions not suitable forthis study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Accomplishment of 4 course treatment

Secondary Outcome Measures

Name	Time	Method
2yr RFS,OS,RDI,Safty